Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

56
Biotech: Take It On The Run

2018-07-05 seekingalpha
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making.
BLCM SLDB GLMD LOXO INCY ARQL NTEC KDMN SRPT MGTX AQXP 4508 IFRX MTZXF ARGX GWPH MTZPY NVS CTMX GWP

0
Merus Announces Annual Meeting of Shareholders

2018-07-05 globenewswire
UTRECHT, The Netherlands, July 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands).
INCY

28
Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

2018-07-03 seekingalpha
RedHill Biopharma (RDHL) announced that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The patents will be in effect until 2029. The company has an important upcoming catalyst related to its RHB-104 candidate. Topline Phase 3 data of RHB-104 trial MAP-US on Crohn's disease expected in early August 2018.
NLNK REDIF ALKS RDHL INCY TLGT OBMP CTIC CTI JAGX SHPG NVTR MRK CELG

0
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer

2018-07-03 zacks
Merck and Co., Inc. (MRK - Free Report) gained priority review for yet another supplemental biologics license application (sBLA) for its PD-1 inhibitor, Keytruda. With the latest application, Merck is looking to get Keytruda approved in combination with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), which is a difficult-to-treat lung cancer patient population.
MRK AMGN INCY

92
Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod

2018-06-27 zacks
The biotech sector was in focus with regular pipeline updates. The key stories include bigwig Gilead Sciences (GILD - Free Report) getting approval for its HIV drug Biktarvy in Europe and Puma Biotechnology (PBYI - Free Report) soaring on positive CHMP recommendation, while Merrimack (MACK - Free Report) plunged on the failure of its phase II study in pancreatic cancer.
AMGN GILD INCY PBYI ICHR

150
Your Daily Pharma Scoop: Heron Spikes, Ironwood Pharma Moves Ahead, Mesoblast Positive

2018-06-27 seekingalpha
The Daily Scoop is going to turn one year soon. Thank you for reading, commenting, and supporting our efforts. Please go to the end of this article to read an important announcement.
IRWD REGN INO RVNC PCRX INCY TROV TNDM SHPG MEOBF MRK SENS HAE MESO HRTX BMY

46
Corvus Pharmaceuticals Remains A High-Risk Investment

2018-06-26 seekingalpha
On June 5, 2018, Jefferies established a price target of $17 per share for Corvus Pharmaceuticals (NASDAQ:CRVS). As I started researching this article on Friday, June 22, Corvus was down 10% on the day to $11.25. Who is right, the market or Jefferies? Or neither? As a small cap biotech investor, making independent determinations is crucial to my financial health.
AGEN INCY CRVS IBB

21
Tuesday’s Biggest Winners and Losers in the S&P 500

2018-06-26 247wallst
June 26, 2018: The S&P 500 closed up 0.2% at 2,722.96. The DJIA closed up 0.1% at 24,281.07. Separately, the Nasdaq was up 0.4% at 7,561.63.
GE GEC INCY GNE

13
Incyte (INCY) Announces Positive Results on Jakafi for GVHD

2018-06-22 zacks
Incyte Corporation (INCY - Free Report) announced that the phase II trial, REACH1, evaluating lead drug Jakafi in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD), met its primary endpoint.
INCY NVS

7
Incyte Plans sNDA for Impressive Jakafi but Forced to Scrap Another Program

2018-06-21 biospace
Shares of Incyte Corporation are up slightly this morning after the company started off its annual R&D day with positive news from its pivotal REACH1 study of Jakafi (ruxolitinib) in steroid-refractory acute graft-versus-host disease (GVHD) and sets up the filing of a supplemental New Drug Application.
INCY

314
Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

2018-06-20 biospace
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
ZYME BLCM NLNK PIRS ARMO RCUS INO IDRAW INCY SRNE JNCE IDRA FATE MRTX CLDX

528
Stocks To Watch: Don't Sleep On Vienna

2018-06-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
NPSNY SYY RUTH LX MS DECK SRRK EQIX JACK MDT TACOW KNSA VZ ZOES FB CLPS QNST MCRI KR SMTC CCL RYDAF EVOP INTC DRRX ICLK MUSA ITUB BB UNFI RHT PTIE HLF JPM MU FNKO HBNC SBUX LOCO PLAY XOM TWX MS.PRE MS.PRF MS.PRG RDSB TOT RDSA MS.PRA SHAK HMNY SAFM BKS AAN OSTK GSKY INCY CTLR CCL BP MS.PRI GOOGL MS.PRK FLL RYDBF MKSI FITB CLR BB PPC BC NDLS DOGZ FND DRI SGBXQ FINL WGO COP XHR DAL ORCL DIS JASO F RDS.B RDS.A TACO DISH TMSR SPTN FDX VLO GOLF CHUY SNY CHEF W ITRM SGBX CVX SNE

182
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space

2018-06-11 zacks
There is no approved therapy that can completely cure autoimmune or inflammatory diseases. The development of new treatment technologies is ongoing. Meanwhile, it is difficult to control autoimmune diseases in the majority of patients. The newest class of medications to treat these diseases is janus kinase (“JAK”) inhibitors, which are providing patients a better treatment option. This class of therapies has generated significant interest due to their better efficacy compared to tumor necrosis factor (“TNF”) inhibitor therapies.
WFC WFCNP WFC.WS AMGN GILD INCY WFC.PRL GLPG WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN ABBV WFC.PRY WFC.PRX PFE WFC.PRW ABBV WFC.PRV

112
Top Analyst Upgrades and Downgrades: Altria, ConocoPhillips, First Data, Match Group, NXP Semiconductor, Seattle Genetics and More

2018-06-11 247wallst
The futures are trading slightly higher Monday morning as investors are hoping for another solid week like the one the markets produced last week, when both the NASDAQ and the Russell 2000 hit new all-time highs. With the second quarter starting to wind down, some of the companies that will be reporting in July could start releasing earnings warnings, so it pays to stay alert now.
SGEN PK WFCNP APA SPWR XEC DTE NXPI WFC.PRL 5GD DTJ WFC.PRJ COP WFC.PRT MTCH WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX KOS WFC.PRW WFC.PRV MO FRAC WFC WFC.WS OLN INCY SRGRF OAS DTW DTV FDC EEFT TRI SEMG DTY

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

1h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Silicon Investor Message Boards

This table lists all message boards related to INCY / Incyte Corp. on message board site Silicon Investor.

Incyte (INCY)
CUSIP: 45337C102